Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
NCT03214172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2018-09-06
Summary
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
Conditions
- Venous Thromboembolism
Interventions
- DRUG
-
Rivaroxaban (Xarelto, BAY59-7939)
15/20 mg
Sponsors & Collaborators
-
Janssen Research & Development, LLC
collaborator INDUSTRY - lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-15
- Primary Completion
- 2017-09-15
- Completion
- 2017-09-15
Countries
- United States
Study Locations
More Related Trials
-
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
NCT02742623 ·Status: COMPLETED
-
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
NCT02504216 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
NCT01619007 ·Status: COMPLETED
-
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
NCT01516814 ·Status: COMPLETED ·Phase: PHASE3
-
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
NCT01516840 ·Status: COMPLETED ·Phase: PHASE3
-
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
NCT02558465 ·Status: COMPLETED
-
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
NCT02064439 ·Status: COMPLETED ·Phase: PHASE3
-
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
NCT01805544 ·Status: COMPLETED
-
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
NCT02111564 ·Status: COMPLETED ·Phase: PHASE3
-
Xarelto Regulatory Post-Marketing Surveillance
NCT01029743 ·Status: COMPLETED
-
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
NCT02502396 ·Status: COMPLETED
-
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
NCT04444804 ·Status: COMPLETED
-
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
NCT00831714 ·Status: COMPLETED
-
Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes
NCT02556203 ·Status: TERMINATED ·Phase: PHASE3
-
Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism
NCT03091621 ·Status: UNKNOWN
-
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
NCT02468102 ·Status: COMPLETED
-
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)
NCT01947998 ·Status: COMPLETED
-
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
NCT05920343 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
NCT03506815 ·Status: COMPLETED ·Phase: PHASE3
-
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
NCT00786422 ·Status: COMPLETED ·Phase: PHASE2
-
Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients
NCT03282643 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database
NCT04923139 ·Status: COMPLETED
-
Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
NCT01436526 ·Status: COMPLETED ·Phase: PHASE1
-
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
NCT00402467 ·Status: COMPLETED ·Phase: PHASE2
-
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
NCT00571649 ·Status: COMPLETED ·Phase: PHASE3